Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. (Q43268894)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19794412%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

title

Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19794412%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19794412%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Alexander S Doney

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19794412%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Mark McCarthy

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19794412%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Chim C. Lang

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19794412%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Ewan Pearson

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19794412%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

K Zhou

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19794412%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

L Donnelly

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19794412%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

L Burch

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19794412%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

R Tavendale

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19794412%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

G Leese

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19794412%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

A T Hattersley

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19794412%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

A D Morris

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19794412%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

language of work or name

English

0 references

publication date

30 September 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19794412%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

8 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19794412%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

volume

87

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19794412%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19794412%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

page(s)

52-56

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19794412%20AND%20SRC:MED&resulttype=core&format=json

Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination.

8 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.176

Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.176

Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.176

Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.176

Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.176

Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.176

Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.176

Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.176

Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. The DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside Scotland. Medicines Monitoring Unit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.176

21 January 2018

Identifiers

DOI

10.1038/CLPT.2009.176

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19794412%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference